Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma

Abstract Background Nivolumab is used for the treatment of malignant pleural mesothelioma (MPM). However, immune-related adverse events (irAEs) occur in patients treated with nivolumab. Several studies have reported the correlation between irAEs and therapeutic effects of immune checkpoint inhibitor...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hiroto Yoneda, Hiroshi Nokihara, Atsushi Mitsuhashi, Ryohiko Ozaki, Yohei Yabuki, Hirokazu Ogino, Kenji Otsuka, Yasuhiko Nishioka
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Immune-related adverse events Malignant pleural mesothelioma Nivolumab Therapeutic effect Diseases of the respiratory system RC705-779
Acceso en línea:	https://doaj.org/article/283e2c804e1e4caca2a024bc86d5df46
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:283e2c804e1e4caca2a024bc86d5df46
record_format	dspace
spelling	oai:doaj.org-article:283e2c804e1e4caca2a024bc86d5df462021-11-21T12:39:20ZCorrelation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma10.1186/s12890-021-01746-61471-2466https://doaj.org/article/283e2c804e1e4caca2a024bc86d5df462021-11-01T00:00:00Zhttps://doi.org/10.1186/s12890-021-01746-6https://doaj.org/toc/1471-2466Abstract Background Nivolumab is used for the treatment of malignant pleural mesothelioma (MPM). However, immune-related adverse events (irAEs) occur in patients treated with nivolumab. Several studies have reported the correlation between irAEs and therapeutic effects of immune checkpoint inhibitor, but none have reported the correlation in MPM. Here we report a retrospective study which shows the correlation between irAEs and therapeutic effects of nivolumab in patients with MPM. Methods This study included patients treated with nivolumab at Tokushima University Hospital from February 2009 to September 2021. We retrospectively reviewed the medical records to evaluate the several clinical factors, such as the presence or absence of irAEs, their severities, progression-free survival (PFS), overall survival (OS) or objective response to the treatment. Results Eleven patients received treatment with nivolumab. Objective response rate was 18.2% and the disease control rate was 90.9%. Median PFS was 6.8 months (95% confidence interval, 1.3 to 11.9 months) and median OS was 15.2 months (95% confidence interval, 8.9 to 21.5 months). IrAEs occurred in eight patients (72.7%), and grade ≥ 2 irAEs occurred in six patients (54.5%). PFS and OS were significantly longer in the grade ≥ 2 irAEs group than in grade < 2 irAEs group (median PFS 13.6 vs. 3.8 months, p = 0.0093; median OS not reached vs. 8.6 months, p = 0.0108). Conclusions This is the first study to report the correlation between irAEs and therapeutic effects in patients with MPM. Because the presence of irAEs may be associated with a favorable clinical outcome, early detection and appropriate management of irAEs will increase the therapeutic benefits to patients.Hiroto YonedaHiroshi NokiharaAtsushi MitsuhashiRyohiko OzakiYohei YabukiHirokazu OginoKenji OtsukaYasuhiko NishiokaBMCarticleImmune-related adverse eventsMalignant pleural mesotheliomaNivolumabTherapeutic effectDiseases of the respiratory systemRC705-779ENBMC Pulmonary Medicine, Vol 21, Iss 1, Pp 1-6 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immune-related adverse events Malignant pleural mesothelioma Nivolumab Therapeutic effect Diseases of the respiratory system RC705-779
spellingShingle	Immune-related adverse events Malignant pleural mesothelioma Nivolumab Therapeutic effect Diseases of the respiratory system RC705-779 Hiroto Yoneda Hiroshi Nokihara Atsushi Mitsuhashi Ryohiko Ozaki Yohei Yabuki Hirokazu Ogino Kenji Otsuka Yasuhiko Nishioka Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
description	Abstract Background Nivolumab is used for the treatment of malignant pleural mesothelioma (MPM). However, immune-related adverse events (irAEs) occur in patients treated with nivolumab. Several studies have reported the correlation between irAEs and therapeutic effects of immune checkpoint inhibitor, but none have reported the correlation in MPM. Here we report a retrospective study which shows the correlation between irAEs and therapeutic effects of nivolumab in patients with MPM. Methods This study included patients treated with nivolumab at Tokushima University Hospital from February 2009 to September 2021. We retrospectively reviewed the medical records to evaluate the several clinical factors, such as the presence or absence of irAEs, their severities, progression-free survival (PFS), overall survival (OS) or objective response to the treatment. Results Eleven patients received treatment with nivolumab. Objective response rate was 18.2% and the disease control rate was 90.9%. Median PFS was 6.8 months (95% confidence interval, 1.3 to 11.9 months) and median OS was 15.2 months (95% confidence interval, 8.9 to 21.5 months). IrAEs occurred in eight patients (72.7%), and grade ≥ 2 irAEs occurred in six patients (54.5%). PFS and OS were significantly longer in the grade ≥ 2 irAEs group than in grade < 2 irAEs group (median PFS 13.6 vs. 3.8 months, p = 0.0093; median OS not reached vs. 8.6 months, p = 0.0108). Conclusions This is the first study to report the correlation between irAEs and therapeutic effects in patients with MPM. Because the presence of irAEs may be associated with a favorable clinical outcome, early detection and appropriate management of irAEs will increase the therapeutic benefits to patients.
format	article
author	Hiroto Yoneda Hiroshi Nokihara Atsushi Mitsuhashi Ryohiko Ozaki Yohei Yabuki Hirokazu Ogino Kenji Otsuka Yasuhiko Nishioka
author_facet	Hiroto Yoneda Hiroshi Nokihara Atsushi Mitsuhashi Ryohiko Ozaki Yohei Yabuki Hirokazu Ogino Kenji Otsuka Yasuhiko Nishioka
author_sort	Hiroto Yoneda
title	Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
title_short	Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
title_full	Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
title_fullStr	Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
title_full_unstemmed	Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
title_sort	correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
publisher	BMC
publishDate	2021
url	https://doaj.org/article/283e2c804e1e4caca2a024bc86d5df46
work_keys_str_mv	AT hirotoyoneda correlationbetweenimmunerelatedadverseeventsandtherapeuticeffectsofnivolumabinpatientswithmalignantpleuralmesothelioma AT hiroshinokihara correlationbetweenimmunerelatedadverseeventsandtherapeuticeffectsofnivolumabinpatientswithmalignantpleuralmesothelioma AT atsushimitsuhashi correlationbetweenimmunerelatedadverseeventsandtherapeuticeffectsofnivolumabinpatientswithmalignantpleuralmesothelioma AT ryohikoozaki correlationbetweenimmunerelatedadverseeventsandtherapeuticeffectsofnivolumabinpatientswithmalignantpleuralmesothelioma AT yoheiyabuki correlationbetweenimmunerelatedadverseeventsandtherapeuticeffectsofnivolumabinpatientswithmalignantpleuralmesothelioma AT hirokazuogino correlationbetweenimmunerelatedadverseeventsandtherapeuticeffectsofnivolumabinpatientswithmalignantpleuralmesothelioma AT kenjiotsuka correlationbetweenimmunerelatedadverseeventsandtherapeuticeffectsofnivolumabinpatientswithmalignantpleuralmesothelioma AT yasuhikonishioka correlationbetweenimmunerelatedadverseeventsandtherapeuticeffectsofnivolumabinpatientswithmalignantpleuralmesothelioma
_version_	1718418874066534400

Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma

Ejemplares similares